Trial Profile
Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2014
Price :
$35
*
At a glance
- Drugs Amifostine (Primary)
- Indications Head and neck cancer; Salivary gland disorders; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Washington University School of Medicine
- 18 Feb 2014 New trial record